Sir: Dopamine agonists, such as carbidopa-levodopa, have utility in alleviating symptoms of movement disorders, e.g., parkinsonism, and can reduce distressing movement disturbances arising from a variety of other conditions, e.g., restless legs syndrome, and tremor arising from head injury. We report a case illustrating that utilization of a dopamine agonist can precipitate tics in a patient with a clinically unrecognized history of tic disorder that had been in remission for years.
Tourette's disorder consists of a combination of vocal and multiple motor tics that generally develop early in childhood, often before 7 years of age, and persist for at least 1 year. 1 There is wide variability in the presentation and severity of Tourette's disorder, i.e., number, type, and duration of symptoms. 2 In milder variants of the disorder, symptoms often decrease as an individual proceeds through adolescence. Mild tic disorders may go unrecognized and fail to receive medical attention. The patient described herein lacked the symptom cluster consistent with classic Tourette's disorder and never required formal dopamine antagonist therapy. His symptoms appeared to be consistent with the variant classified as transient tic disorder. 1 Dopaminergic excess has been postulated to underlie the pathophysiology of Tourette's disorder. 2, 3 This postulation has been based upon the observation that dopamine antagonists mitigate tics, while dopamine agonists, e.g., levodopa, and stimulants, e.g., methylphenidate, may exacerbate them. 3, 4 However, data are emerging that suggest that dopamine agonists may have a role in reducing tic severity. 5 Such conflicting lines of evidence suggest that much has yet to be learned about the pathophysiology of Tourette's disorder and its variants.
What is striking in the case presented here is that administration of levodopa appeared to result in a recrudescence of a previously dormant tic disorder. The temporal relationship between the initiation of carbidopa-levodopa and the onset of motor and vocal tics in this patient, along with the rapid cessation of symptoms shortly after drug discontinuation, suggests that the medication was responsible for the tic recrudescence observed in our patient. It is possible that the central nervous system injury sustained may have rendered him vulnerable to untoward effects of dopamine augmentation. Use of dopamine agonists in medical and/or surgical patients can potentially complicate their clinical course, particularly if a current or remote history of tic disorder is overlooked or ignored.
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Sir: In a recent supplement of the Companion, the utilization of benzodiazepines in clinical practice was reviewed. 1 In that supplement, several authors advised caution in prescribing benzodiazepines to patients with histories of alcohol (p. 5) or substance abuse (p. 23). We were curious about the actual percentage of patients for whom this precaution might apply. Data are from the 4 studies in which data on substance abuse other than alcohol abuse (Dick et al., 5 Katerndahl and Realini, 6 Mavissakalian and Guo, 7 and Sbrana et al. 9 ) were reported.
To explore this, we undertook a literature search dating back to 1990 using the PsycINFO and MEDLINE databases. We entered the search terms panic disorder, substance abuse, and alcohol. After identifying and gathering articles, we excluded those that had already been addressed in review articles, were written in foreign languages, or reported studies that comprised adolescent participants.
We first examined the lifetime prevalence of alcohol and substance abuse in studies in which participants were identified by a diagnosis of panic disorder. As a prelude to our findings, we encountered a 1990 review article by Brady and Lydiard 2 that reported 2 earlier studies in which the prevalence of alcohol abuse or alcoholism was 7% to 8% among panic disorder samples. We located 7 studies published since 1990 ( Table 1) that explored the lifetime prevalence of alcohol and substance abuse in participants with panic disorder. [3] [4] [5] [6] [7] [8] [9] Because the study by Lepine et al. 4 did not separate alcohol from substance abuse, we elected to exclude it from the present analysis, bringing the subsequent working sample size to 844 participants. In this subsample, 150 participants (17.7%) with panic disorder were also diagnosed with alcohol abuse or dependence. As for "other substance abuse," again excluding the Lepine et al. study, 4 4 studies comprising 500 participants were relevant. The prevalence of other substance abuse was confirmed in 111 participants (22.2%). In summary, these data indicate that in studies since 1990, approximately 20% of panic disorder patients had lifetime histories of either alcohol or other substance abuse.
To augment the preceding findings, we examined 2 large community studies that explored the prevalence of alcohol and substance abuse in panic disorder participants during the 12 months preceding assessment. In the first study, 10 the prevalence rate of panic disorder among 9282 participants was 2.7%; the correlations between panic disorder and alcohol abuse, alcohol dependence, drug abuse, and drug dependence were 0.27 (significant at p < .05), 0.25, 0.16, and 0.27, respectively. In the second study, 11 the prevalence of any comorbid alcohol use disorder during the preceding 12 months in panic disorder participants with and without agoraphobia was 18.8% and 15.3%, respectively, while the prevalence of any comorbid substance abuse disorder was 24.2% and 17.3%, respectively.
We next examined the prevalence of panic disorder in study samples of alcoholics or substance abusers. Brady and Lydiard
